Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook



 

Screening for Alzheimer's Disease?

14 April 2009

By Alison Cranage

Science Communications Officer, the Alzheimer's Research Trust

Appeared in BioNews 503
This week BioNews reports a study that shows a gene variant (APOEe4) known to increase the risk of Alzheimer's disease is involved in the way our brains function (1). Some headlines stated that 'people could be screened for Alzheimer's disease risk', but at the moment it is not easy to diagnose the condition, and even more difficult to predict who will develop it. The causes of Alzheimer's disease are not fully understood, and the consequences devastating. Unfortunately, we are all at some degree of risk and, with ever increasing numbers of people affected, there is an urgent need for effective treatments.

It has been known for 15 years that the APOEe4 gene variant is a risk factor for late onset Alzheimer's disease. The APOE gene exists in several forms (e2, e3 and e4) - and large population studies have shown that the e4 variant increases a person's risk of developing the condition (2). However, the APOEe4 variant is common - a quarter of the UK population have at least one copy - and most people with it will not develop Alzheimer's disease. Equally, many people with Alzheimer's disease do not have the APOEe4 gene. Alzheimer's disease is a complex disease not fully understood, with many interacting causes, both genetic and environmental. Knowing whether someone has the APOEe4 gene is not, therefore, an accurate predictor of their risk of developing the disease.

In the recently reported study, researchers looked at the difference in brain activity between two groups of healthy young people, half (18) of which had the APOEe4 gene (3). The researchers used fMRI to study brain activity in the two groups when they were performing memory tasks and when they were at rest. They found distinct patterns: those with APOEe4 had greater activation in areas of the brain involved in memory formation than those without. This difference was seen even when the participants were not doing any memory tasks. They hypothesise that APOEe4 can modulate brain function decades before any clinical or physiological expression of neurodegeneration appears.

To determine whether the activation seen in this study has any bearing on a person's risk of developing disease, the participants need to be studied over a long time period. At the moment, the results do not help us to differentiate e4 carriers who will go on to develop Alzheimer's disease from those who will not.  It does pave the way for further studies that could help us understand how brain function in younger adults may contribute to the development of Alzheimer's disease later in life.

Each new piece of work like this brings scientists closer to understanding what is happening in the brain as we age, and how it can go wrong in neurodegenerative disease. Increasing public awareness of dementia has brought the disease into the spotlight, and people are willing to speak out about a disease that was once hidden in the shadows. Much more work needs to be done to discover the risk factors and causes of dementia. Further research will likely lead to ways to prevent and treat it.

At the moment, Alzheimer's disease is difficult to diagnose. Diagnosis involves ruling out other causes of symptoms and can only be confirmed post-mortem by looking at the 'plaques' and 'tangles' of proteins that are the pathological hallmarks of the disease. An accurate diagnostic test is desperately needed. Many researchers believe that the disease process starts 10-15 years before any clinical symptoms appear. This is the time then, when treatments are likely to be the most effective and therefore clinicians need to be able to identify those people that need them.

At the moment effective treatments are not available, while current treatments halt only some symptoms for a time. It is not all doom and gloom however; there are about 13 drugs in phase three clinical trials that aim to slow down or halt the progression of the disease. If just one of these is successful and can prevent the onset of the disease by just five years, the number of people dying with Alzheimer's disease will halve.

Research is building up an ever more accurate picture of dementia, and hopefully will lead us to the answers we need. The number of people with dementia is expected to reach 120 million globally by 2050 (4), and treatments have never been more urgently needed.

 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

18 July 2016 - by Chris Hardy 
A gene variant linked to increased risk of Alzheimer's disease may affect memory and thinking skills in children, a study has found...
11 April 2011 - by Alison Cranage 
International scientists including researchers at Cardiff University, UK and the University of Pennsylvania, USA have discovered five genetic variations associated with Alzheimer's disease. The findings are published in two papers in the journal Nature Genetics...
07 September 2009 - by Ailsa Stevens 
British and French researchers this week announced the discovery of three new genes linked to late-onset Alzheimer's disease, certain variations in which may increase a person's risk of developing the disease by 10-15 per cent. If new drugs could be developed to counter the effects of these mutations, it could help to prevent 20 per cent, the equivalent of 100,000 cases, of Alzheimer's disease in the UK per year, the researchers claim....
19 July 2009 - by Adam Fletcher 
Findings published last week suggest that people are not troubled upon learning they are at higher risk of developing Alzheimer’s disease. Writing in the New England Journal of Medicine, researchers at the Boston University School of Medicine, US, led by Dr Robert Green, measured participants’ anxiety levels following results of a genetic test. The paper arrives amidst debate on how harmful direct-to-customer genetics testing - offered by companies such as 23andMe and DeCodeMe - might actuall...

14 April 2009 - by Ailsa Stevens 
Scientists from the UK's Oxford University and Imperial College London have shown that carriers of a gene variant which increases Alzheimer's risk by up to ten times may have increased brain activity in a key area of the brain, long before symptoms of the disease develop. The...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation